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Introduction: Idiopathic normal pressure hydrocephalus (iNPH) can be misdiagnosed
with other neurodegenerative diseases, especially in the early disease stages. Considering
the opportunity of the shunt surgery, iNPH should be diagnosed with accuracy. Here, we
evaluate the utility of CSF biomarkers and their relationship with clinical features in the
diagnosis of iNPH.
Methods: We performed a multivariate analysis of the CSF levels of Aβ42, t-tau, and
p-tau collected from four groups of patients: 14 iNPH, 14 progressive supranuclear
palsy (PSP), 14 Alzheimer’s disease (AD), 14 controls (CTL). Diagnostic accuracy of
biomarkers was determined by the receiver operating characteristic curve analysis. Sta-
tistical correlation was calculated between each CSF biomarker and single clinical items
of iNPH.
Results: Aβ42 levels in iNPH were lower than controls, although not as low as in AD.
Likewise, CSF t-tau and p-tau were lower in iNPH than in controls. Of interest, t-tau and
p-tau were higher in AD than in controls and hence both t-tau and p-tau were significantly
lower in iNPH than in AD. No differences were found between iNPH and PSP. CSF
biomarkers levels did not correlate to clinical features of iNPH, whereas two significant
correlations emerged within clinical parameters: cognitive impairment was related to gait
difficulties, while ventricular enlargement correlated with continence disturbances.
Conclusion: Measurement of CSF biomarker levels may be helpful in the differential
diagnosis between iNPH and AD but not between iNPH and PSP. Both Aβ42 and tau
levels appear unrelated to main clinical features of iNPH.
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Introduction
Idiopathic normal pressure hydrocephalus (iNPH) is a syndrome characterized by enlargement
of ventricular size with normal intracranial pressures along with the classic triad of dementia,
gait disturbances and urinary incontinence (1, 2). However, early clinical features of iNPH may
be subtle and lead to misdiagnosis with either neurodegenerative disorders or cerebrovascular
diseases (1, 3). Indeed, the frontal dysexecutive syndrome, the most commonly reported cognitive
profile of iNPH (4), is frequently observed in progressive supranuclear palsy (PSP) (5). Likewise,
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the characteristics of gait impairment observed in iNPH may not
be of univocal interpretation, at least to some extent, thereby
representing a confounding factor in the differential diagnosis
with parkinsonian syndromes (3, 4). Therefore, considering that
iNPH symptoms can be alleviated by appropriate shunt surgery
(1), an improved accuracy in the diagnosis of iNPH should be
pursued.
Recent studies support the usefulness of a combination of var-
ious CSF biomarkers of neurodegeneration to increase diagnostic
accuracy during early phases of neurodegenerative diseases and
iNPH (4, 6, 7). In this study, wemeasured a panel of CSF biomark-
ers, including 42 amino-acid forms of amyloid-β (Aβ42), total tau
protein (t-tau), and phosphorylated tau protein (p-tau), to find
elements supporting the differential diagnosis between iNPH and
other neurodegenerative diseases. In addition, we performed a
correlation analysis between clinical and biochemical features of
iNPH.
Subjects and Methods
Subjects and Clinical Assessment
We enrolled a total of 56 subjects receiving lumbar puncture
(LP) for diagnostic purposes admitted to the Neurology Unit of
Policlinico Tor Vergata, Rome – Italy between 2012 and 2014.
Subjects were divided into four groups. iNPH (n= 14), diag-
nosed according to iNPH guideline criteria for possible iNPH (8).
Although both clinical and MRI criteria are considered sufficient
to diagnose a possible iNPH (8), all iNPH patients underwent the
spinal tap-test as further supportive diagnostic procedure (1, 8, 9).
We considered a positive test if, 3 h after CSF drainage (30ml),
the time needed to walk 10m (10-m straight walking test) was
reduced by>20% (9).
For Alzheimer’s disease (AD) (n= 14) and PSP (n= 14), diag-
nosis was made according to internationally established opera-
tional criteria (10, 11). AD and PSP patients had mini mental
state evaluation (MMSE) <26. Controls (CTL, n= 14) were non-
demented patients, without evidence of other neurodegenerative
disorders, undergoing LP for suspected chronic polyneuropathy.
Before the CSF tap-test, iNPH patients underwent a rigorous
assessment: cognitive decline was established through a complete
psychometric evaluation (MMSE, Ray words test, Raven test,
Rey–Osterrieth Complex Figure Test, Stroop test, verbal fluency
test); the MMSE score, adjusted by age and educational level,
was used as cognitive decline index. Gait and continence were
estimated with the respective ordinal rating domain of the new
iNPH scale (12); gait score was assigned observing tandem gait
and turning (12). Evan’s index (EI) (8) was calculated through CT
or MRI brain scans.
CSF Sampling and Analysis
Lumbar puncture was performed following standard procedures
as described previously (13, 14). All subjects were punctured in
the morning of the same day of the clinical evaluation, lying
in lateral position with atraumatic needles. CSF was collected
in polypropylene tubes using standard sterile techniques. Blood
specimens were also obtained at the same time of LP. Immediately
after collection, CSF samples were stored on ice, sent to the local
laboratory, and processed within 1 h. The first CSF sample was
used for chemical andmicroscopic analysis (CSF samples contain-
ing >4 cells/µl would be excluded). The second sample was used
for the determination of biomarkers levels through commercially
available sandwich enzyme-linked immunosorbent assays follow-
ing standard procedures (13, 14). To improve diagnostic accuracy,
the Aβ42/p-tau ratio was calculated for each group (15). All
procedures were carried out with the appropriate understanding
and written consent of the subjects.
Statistical Analysis
A multivariate analysis of variance (MANOVA) with simple con-
trast was used to test the hypothesis of significance of the iNPH
status as a factor compared to AD, PSP, and CTL for Aβ42, t-tau,
and p-tau levels. The model was corrected for the main covariates
in this study (age, gender, total CSF proteins, BBB index). Sen-
sitivity and specificity of each biomarker were determined by the
receiver operating characteristic (ROC) curve analysis, calculating
the area under the curve (AUC), and the cut-off points. The
Spearman’s correlation was used to test the association between
Aβ42, t-tau and p-tau levels, total CSF proteins, BBB index in
iNPH patients with other variables representative of the main
clinical features of iNPH (MMSE, EI, gait and continence scores,
disease’s duration). Statistical analysis was performed with SPSS
20, except for the power analysis, performed with GPower3.1.3.
Data are presented as means SD.
Results
Demographic data and biomarker levels for each group are sum-
marized in Figure 1. Clinical data of iNPH are reported inTable 1.
Fourteen iNPH patients, 8 males and 6 females, had a mean age
of 73.21 4.63 years. Disease duration was 18.14 8.75months.
MMSE score was 22.72 4.95. Gait score was 4.21 1.72. Conti-
nence score was 2.64 1.34. EI was 0.33 0.02.
Power analysis showed that a MANOVA model with 1 inde-
pendent and 3 response variables, with 4 groups and a sample size
of 56, reaches a power of 99% at a type I error level of 5% for a
Cohen’s f 2 of 0.2. The critical value of Spearman’s Rho coefficient
for N = 14, a type I error level of 5%, and a two-tailed test was
0.538 (16). Statistical significance was assessed for a p< 0.05.
Mean levels of CSF biomarkers are significantly different
among considered groups [F(3, 45)= 8.402, p< 0.01, Pillai’s
trace= 1.047, partial η2= 0.349] (Figure 1B).
CSF t-tau [F(3, 47)= 29.7, p< 0.01, partial η2= 0.655] levels
were slightly lower in iNPH than in CTL, although this result was
far from statistical significance (p= 0.352). No significant differ-
ence was found between iNPH and PSP (p= 0.509). Conversely, t-
tauwas significantly lower in iNPHcompared toAD (p< 0.01). To
this regard, the ROC analysis provided an AUC of 0.99 (p< 0.01)
and a cut-off value of t-tau <386 pg/ml (100% of sensitivity;
93.8% of specificity) in the discrimination of iNPH from AD
(Table 2). Similar data were obtained with p-tau measurements
[F(3, 47)= 20.2, p< 0.01, partialη2= 0.563]. CSF p-tauwas lower
in iNPH than in CTL (p= 0.068) whereas no difference was mea-
sured with PSP (p= 0.114). Likewise, p-tau was lower in iNPH
compared to AD (p< 0.01). ROC curve analysis provided anAUC
of 0.99 (p< 0.01) and a cut-off value of p-tau<46 pg/ml (100% of
Frontiers in Neurology | www.frontiersin.org April 2015 | Volume 6 | Article 862
Schirinzi et al. CSF biomarkers in iNPH
FIGURE 1 | Demographical and biochemical profiles of groups. (A) No
statistical differences exist regarding the distribution of age and gender among
the groups. Aβ42/p-tau ratio was calculated considering ratio values <6.43 as
AD,6.43 as non-AD (14). Aβ42/p-tau ratio of AD group is significantly different
(p<0.01) from other groups. (B) Statistical differences of biomarkers
concentrations among the groups. Asterisks indicate p<0.05.
TABLE 1 | Clinical data of iNPH.
Patients Age Disease
duration
(months)
Gait
score
MMSE Continence
score
Evan’s
index
1 73 24 6 25:7 2 0.31
2 64 12 2 25:7 3 0.33
3 77 3 2 26:3 1 0.31
4 73 24 3 23:7 1 0.36
5 68 24 4 18 3 0.34
6 69 7 6 14:9 4 0.37
7 76 24 6 19:7 2 0.34
8 74 18 3 24:4 2 0.32
9 81 5 5 23:4 3 0.31
10 77 30 3 25 3 0.33
11 77 20 7 17:7 5 0.34
12 72 30 6 21:7 1 0.33
13 68 18 3 26:2 5 0.35
14 76 15 3 25:7 2 0.34
Mean 73.21 18.14 4.21 22:72 2.64 0.33
SD 4.63 8.75 1.72 4:95 1.34 0.02
TABLE 2 | ROC curve analysis and cut-off values of CSF biomarkers levels
in differential diagnosis between iNPH and AD.
t-tau p-tau Aβ42 Aβ42/t-tau
AUC 0.99 0.99 0.75 1
Cut-off value <386pg/ml <46pg/ml >371pg/ml >6.43
Sensitivity (%) 100 100 73.30 100
Specificity (%) 93.8 93.8 81.30 93.80
sensitivity; 93.8% of specificity) in discriminating iNPH from AD
(Table 2). Collectively, our data show that both t-tau and p-tau are
higher in AD than in CTL and hence the CSF t-tau and p-tau are
much lower in iNPH than in AD.
CSF Aβ42 levels in iNPH group [F(3, 47)= 16.3, p< 0.01,
partial η2= 0.509] was significantly lower than in CTL (p< 0.01),
though even lower levels were measured in AD (p= 0.01). No
significant difference was found compared to PSP (p= 0.739).
With respect to AD, ROC curve analysis provided an AUC
of 0.75 (p= 0.02) and a cut-off value of Aβ42 >371 pg/ml
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(73.3% of sensitivity; 81.3% of specificity) to differentiate iNPH
from AD (Table 2).
Our measurements were complemented by calculation of the
mean values of Aβ42/p-tau ratio (15), summarized in Figure 1A.
Notably, Aβ42/p-tau ratio values were fourfold lower in AD than
in iNPH, suggesting that measurement of such ratio may sig-
nificantly increase diagnostic accuracy in differentiating iNPH
from AD. ROC analysis provided an AUC of 1.00 (p< 0.01).
At the given cut-off value of 6.43 (15), we measured 100% of
sensitivity and 93.8%of specificity in distinguishing between these
diseases.
Correlation analysis showed no significant associations
between t-tau, p-tau, Aβ42, total CSF proteins, and BBB index
with iNPH clinical parameters. A negative correlation between
MMSE and gait score (Rho 0.743, p< 0.01) was found, whereas
a positive correlation was found between EI and continence score
(Rho 0.594, p< 0.05). Values for each clinical parameter analyzed
are reported in Table 1.
Discussion
Idiopathic normal pressure hydrocephalus remains a contro-
versial entity, believed to be determined by an imbalance in
CSF turnover (1, 2, 7, 8). Notably, a significant proportion
of the relatively few patients coming to autopsy have been
shown to have co-existing neurodegenerative or vascular patholo-
gies (3). Indeed, despite the potential different pathogeneses,
some clinical features of iNPH, such as cognitive decline with
selective impairment of the executive functions and attention
(1, 4, 5), gait disturbances (3, 4), urinary urgency (17), and
enlarging of ventricular system (18) may overlap with other
neurodegenerative diseases such as AD and PSP. Considering
the different therapeutic options, including CSF shunting for
iNPH (1, 8), the search for better diagnostic investigations is
mandatory.
It is well known that Aβ42 is reduced in CSF of patients
with iNPH (4, 6, 7, 19). A number of different causes have
been proposed to explain such reduction including a decreased
production of amyloid-derived proteins, their impaired clearance
from the extracellular fluid or their extracellular accumulation (7),
or, finally, an aging-related phenomenon (20). Conversely, the
literature reports no univocal changes of t-tau and p-tau levels in
patients with iNPH (4, 6, 7, 19). In particular, the reduction of
tau proteins has been referred to a phenomenon of dilution in the
increased CSF volume of iNPH (4, 7).
In our study, we found that CSF levels of t-tau and p-tau are
higher in AD than in CTL and hence t-tau and p-tau are much
lower in iNPH than in AD, allowing to differentiate iNPH from
AD. Furthermore, we observed that CSF Aβ42 levels of iNPH
are lower than in CTL but not as low as it is in AD. Despite the
small sample, our analysis provides plausible threshold values for
CSF levels of t-tau, p-tau, and Aβ42/p-tau ratio, although larger
samples are necessary to confirm these observations. Conversely,
this panel of CSF biomarkers is not sufficient to discriminate
iNPH from PSP.
Our findings also indicate that clinical parameters of iNPH, and
in particular both cognitive decline and gait disturbances, despite
the significant reduction of Aβ42 levels, are unrelated either to the
β-amyloid pathology or to a tau-related degenerative process (7).
However, it must be pointed out that these findingsmay have been
affected by the relatively small number of subjects that warrants
further investigations on larger sample groups.
Despite such limitation, our data suggest that the analysis of
CSF biomarkers might be of support in the differential diagnosis
of these different conditions, particularly in view of the distinct
therapeutic options.
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